UBS Maintains a 'Buy' on CVS Caremark (CVS); Post-Call: Plenty of Positive Datapoints

UBS maintains a 'Buy' on CVS Caremark (NYSE: CVS) price target raised from $44 to $45.

UBS analyst says, "CVS Discussed Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) Dispute and ESRX / Medco Health (NYSE: MHS) Merger on 3Q CC - On the key topic of market share in the retail segment, CVS did confirm that its robust retail growth in 3Q11 likely outpaced the industry, but mgmt was quick to mention that the ongoing WAG/ESRX dispute had very little to do with it. On the flipside, CVS mgmt does agree that the upside potential from this shakeout could be material in 2012, but the company will not incorporate such upside into its initial 2012 EPS guidance to be provided at the analyst day on Dec 20th. The same seemed to be true of any business capture from the proposed ESRX/MHS merger."

For more ratings news on CVS Caremark click here and for the rating history of CVS Caremark click here.

Shares of CVS Caremark closed at $37.31 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• KKR Real Estate Financial Trust (KREF) PT Lowered to $12 at JMP Securities
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI